Magic mushrooms take on depression: new trial tests psilocybin with antidepressants

NCT ID NCT06898606

Recruiting now Symptom relief Sponsor: Federal University of Latin American Integration Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a single dose of psilocybin mushrooms, combined with therapy, can help adults with treatment-resistant depression. Half of the 24 participants will also take the antidepressant fluoxetine to see if it changes the effects. The main goal is to measure mood improvement after 4 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Psilocybin (from Psilocybe cubensis mushrooms)
What this could lead to: If it works, this could point toward a new treatment option for people with depression that hasn't improved with standard medications.
What could go wrong: This is a small, early-phase trial with only 24 participants, so results may not apply to everyone. The psychedelic experience can be intense and may cause temporary distress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression depressive disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSIVE DISORDER

Contacts and locations

Locations

Federal University of Latin American Integration
RECRUITING

Foz do Iguaçu, Paraná, 85870-650, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.